Drospirenone

PBAC's latest decision on Drospirenone: Recommended with restriction (2024). Considered for Contraception in women. Drospirenone is a progestogen-only pill (POP) indicated for women requesting contraception, particularly those with contraindications to estrogen-containing combined oral contraceptives.

Eligible population

Healthy women at risk of pregnancy who are sexually active and requesting contraception, particularly those with contraindications to estrogen-containing combined oral contraceptives. Excludes breastfeeding women and those under 18 years of age (as per trial exclusion criteria).

Therapy area

Women's health

Line of therapy

Any

Evidence base

RCT

Primary endpoint

Pregnancy rate (Pearl Index)

Pivotal trial size

713 patients

Key trials

CF111/301, CF111/302, Korver 1998

Comparator

levonorgestrel 30 microgram tablets (Microlut) and norethisterone 350 microgram tablets (Noriday)

Economic model

Cost-minimisation

ICER note

Cost-effectiveness analysis conducted on a break-even basis (cost neutrality); no specific ICER range stated as numeric values.

Similar precedents

• Estetrol with drospirenone
  similarity 0.72
• Etonogestrel with ethinylestradiol
  similarity 0.66
• Medroxyprogesterone acetate
  similarity 0.66
• Progesterone
  similarity 0.66
• Drospirenone with ethinylestradiol
  similarity 0.65
• Estradiol; progesterone; estradiol and progesterone combination
  similarity 0.62